Entry Inhibitors in Development
 ARV Pipeline: Dolutegravir, TAF (GS-7340), MK-1439 and Cenicriviroc (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- CCR5/CCR2 Antagonist Cenicriviroc: 24-Week Data vs. Efavirenz in ART-Naive (March 8, 2013)
From National AIDS Treatment Advocacy Project
- New Drug Hits HIV and Inflammatory Processes (March 7, 2013)
From MedPage Today
- New Antiretroviral Agents: Cenicriviroc (Video) (March 7, 2013)
From HIVandHepatitis.com
 New HIV Drug Cenicriviroc Shows Non-Inferiority to Efavirenz and Activity Against Inflammation, Study Finds (March 6, 2013)
In The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), from TheBodyPRO.com
- Dual CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-Inflammatory Effects (March 4, 2013)
From HIVandHepatitis.com
- Long-Acting Drug in Development (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- An Overview of PRO-140 (October 22, 2012)
From AIDSinfo
- An Overview of Ibalizumab (October 22, 2012)
From AIDSinfo
- An Overview of Cenicriviroc (October 22, 2012)
From AIDSinfo
- An Overview of BMS-663068 (October 22, 2012)
From AIDSinfo
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Once-Weekly and Once-Monthly HIV Meds in the Pipeline: Studies From ICAAC 2012 (September 17, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
- New Long-Acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies (September 11, 2012)
From HIVandHepatitis.com
- Long-Acting Fusion Inhibitor Albuvirtide Looks Promising in Early Studies (September 11, 2012)
From aidsmap.com
- Tobira Therapeutics Initiates Phase 2b Trial of Cenicriviroc (July 5, 2011)
From Test Positive Aware Network
- Cenicriviroc for Inflammation and HIV (October 25, 2010)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
- Study Closes Vicriviroc Story (September 15, 2010)
From MedPage Today
- TBR-652 Inhibits HIV, May Reduce Inflammation (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- An Anti-Inflammatory Antiretroviral? CCR5/CCR2 Antagonist TBR-652 Monotherapy Study Results: A Blog Entry by Myles Helfand (July 19, 2010)
In The XVIII International AIDS Conference, from TheBodyPRO.com
- TBR-652: A CCR5 Antagonist -- With Anti-Inflammatory Properties? (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
